At the 24th Congress of the European Hematology Association (EHA), Marie José Kersten from the Amsterdam UMC, Amsterdam, NL, talks about access and implementation of chimeric antigen receptor (CAR) T treatment in lymphomas.
Professor Kersten stated in the coming years, we need to increase access to these therapies in Europe and overcome the challenges in implementation. These include delivering the therapy to the patient and managing the side effects which will inevitably lead to a busy time for hematologists in the field.
Professor Kersten stated that the EHA were trying to make delivering CAR T easier for centers - though training and education are the main priority. This is true for both treatment centers and referral centers as it is Professor Kersten's opinion that timely referral and appropriate patient selection is crucial.